Mission Statement, Vision, & Core Values (2026) of China National Accord Medicines Corporation Ltd.

As a subsidiary of Sinopharm Group, China National Accord Medicines Corporation Ltd. has grown into a distribution and retail powerhouse-serving hospitals, pharmacies and community health centers nationwide-and with reported business revenue exceeding 70 billion yuan (about $9.82 billion) in 2021 it ranked 50th among Guangdong's Top 500 enterprises and 23rd among Shenzhen's Top 100, while its stated mission to deliver professional healthcare services to hundreds of millions of people drives a vision to become a high‑quality, easily accessible integrated wholesale‑and‑retail platform and a business model that now includes retail clinics, direct retail, medical equipment and consumables and strategic partnerships such as with Walgreens Boots Alliance to expand trusted retail presence-anchored by core values of integrity, innovation, quality, social responsibility and collaboration that shape its strategic choices and operational priorities.

China National Accord Medicines Corporation Ltd. (000028.SZ) - Intro

• Founded within the Sinopharm ecosystem to integrate wholesale and retail healthcare channels.
• 2021 business revenue: >70 billion yuan (~$9.82 billion).
• Rankings (2021): 50th among Guangdong Top 500 Enterprises; 23rd among Shenzhen Top 100 Enterprises.
• Business lines: hospital distribution, retail pharmacies, retail clinics, medical equipment & consumables, direct-to-consumer retail.
• Strategic alliances include partnerships with global retail players such as Walgreens Boots Alliance Inc.

Mission

To be a high-quality provider of pharmaceutical and healthcare products and services that enhances accessibility, safety and efficiency across China's healthcare system by integrating wholesale and retail channels, optimizing logistics and delivering patient-centered services.

Vision

To become China's leading integrated healthcare supply and retail platform - trusted by hospitals, communities and consumers - enabling broader access to medicines, streamlined supply chains and innovative retail-healthcare formats.

Core Values

• Patient-centered care: prioritize safety, quality and accessibility of medicines and services.
• Integrity and compliance: strict adherence to regulations and ethical supply practices.
• Operational excellence: continuous optimization of logistics, procurement and retail operations.
• Collaboration and partnership: build ecosystems with hospitals, suppliers and retail partners.
• Innovation for service: adopt digital platforms, retail clinic models and data-driven supply chain solutions.

Strategic Focus Areas & KPIs

Key operational and financial metrics guide the company's strategy across wholesale and retail segments:

How Mission, Vision & Values Translate into Operations

• Wholesale scale: centralized procurement and distribution lower costs and improve supply reliability for hospitals.
• Retail integration: expanding community pharmacies and retail clinics to improve last-mile access to medicines and basic healthcare.
• Quality assurance: compliance programs, cold-chain logistics and supplier audits to ensure medicine safety.
• Digitalization: investments in supply-chain IT, e-commerce channels and data analytics to optimize inventory and consumer services.
• International collaboration: leveraging partner expertise to professionalize retail operations and customer experience.

For historical context, ownership structure and deeper analysis of how the company operates and makes money, see China National Accord Medicines Corporation Ltd.: History, Ownership, Mission, How It Works & Makes Money

China National Accord Medicines Corporation Ltd. (000028.SZ) - Overview

China National Accord Medicines Corporation Ltd. (000028.SZ), historically associated with Sinopharm Accord, positions itself as a large-scale professional healthcare services provider focused on improving public health across China. The company's stated mission emphasizes delivering professional, accessible, and reliable pharmaceutical and healthcare services to "hundreds of millions of people," reflecting both scope and social responsibility.

Mission Statement

To provide professional healthcare services to hundreds of millions of people in China by ensuring accessible, reliable, and quality pharmaceutical and related healthcare solutions.

• Deliver professional healthcare services across urban and rural settings.
• Ensure accessible medicines distribution and pharmaceutical support for large population segments.
• Commit to quality, safety, and service excellence in all healthcare interactions.
• Expand from traditional pharmaceutical distribution toward integrated healthcare solutions.

Vision

To be a national leader in comprehensive healthcare delivery - bridging pharmaceuticals, logistics, clinical support, and digital healthcare - and to improve health outcomes for hundreds of millions of Chinese citizens through scalable, high-quality services.

• Scale integrated healthcare services across provinces and community levels.
• Leverage logistics and distribution networks to reduce regional disparities in medicine access.
• Adopt digital solutions to support prevention, diagnosis, and continuity of care.

Core Values

• Professionalism: Upholding clinical and pharmaceutical expertise in service delivery.
• Accessibility: Reducing barriers to medicines and healthcare services nationwide.
• Quality & Safety: Maintaining strict quality controls across sourcing, storage, and distribution.
• Social Responsibility: Prioritizing public health impact for large population cohorts.
• Innovation: Expanding into integrated, value-added healthcare services beyond distribution.

Operational and Impact Metrics

The following table synthesizes publicly discussed scale and operational figures that align with the company's mission to serve very large population segments. These metrics illustrate reach, capacity, and financial positioning relevant to stakeholders and public-health impact.

For investors and readers seeking a financial deep-dive and key quantitative indicators to pair with the above mission and operational context, see: Breaking Down China National Accord Medicines Corporation Ltd. Financial Health: Key Insights for Investors

China National Accord Medicines Corporation Ltd. (000028.SZ) - Mission Statement

• Deliver consistently superior product quality through rigorous quality control, regulatory compliance, and supplier management.
• Ensure wide accessibility of medicines and healthcare products via an expansive wholesale network and retail footprint.
• Integrate upstream wholesale capabilities with downstream retail channels to optimize distribution efficiency and customer convenience.
• Support public health objectives and community healthcare through partnerships, professional services, and patient education.
• Maintain sustainable growth and profitability while reinvesting in innovation, logistics, and digital service platforms.

• Quality leadership: continuous improvement in Good Supply Practice (GSP) and quality assurance systems.
• Accessibility: expanding retail touchpoints and e‑commerce presence to reach urban and rural customers.
• Integrated platform: unified inventory, pricing and customer service across wholesale and retail for faster fulfillment.
• Service orientation: pharmacy professional services, chronic disease management support, and community health initiatives.
• Digital transformation: investments in logistics automation, ERP integration, and customer engagement platforms.

• Expand retail network and omni‑channel presence to increase accessibility, targeting incremental outlet and online order growth.
• Enhance supply‑chain integration between wholesale warehouses and retail pharmacies to lower distribution costs and improve availability.
• Improve product mix toward higher‑margin healthcare services and consumer health products while preserving essential drug supply roles.
• Invest in digital infrastructure (ERP, CRM, last‑mile logistics) to create a seamless wholesale‑to‑retail customer experience.
• Strengthen compliance, pharmacovigilance, and quality assurance to sustain trust and regulatory standing.

China National Accord Medicines Corporation Ltd. (000028.SZ) - Vision Statement

• Integrity: transparency, regulatory compliance, and ethical conduct across procurement, manufacturing, and distribution.
• Innovation: sustained investment in R&D, biotech collaborations, and digital transformation to shorten time-to-market for critical therapies.
• Quality assurance: end-to-end GMP processes, batch-level traceability, and pharmacovigilance to ensure product safety and efficacy.
• Social responsibility: community health programs, environmental stewardship, and responsible sourcing to support population-level wellbeing.
• Collaboration: strategic partnerships with research institutions, hospitals, distributors, and global partners to scale impact.

• Integrity → KPI: regulatory inspection pass rate (target: 100%), compliance-related incident reduction.
• Innovation → KPI: number of pipeline assets and patents (target: double-digit patent families; incremental 10-15% annual R&D output growth).
• Quality assurance → KPI: product recall rate (target: 0%), batch release lead times, CAPA closure rates.
• Social responsibility → KPI: percent reduction in carbon intensity, patient assistance program reach (hundreds of thousands served annually).
• Collaboration → KPI: number of strategic alliances, percentage of revenue from partnered/co-developed products.

• Scaling R&D platforms: expanding biologics and controlled-substance product pipelines and accelerating clinical-translational partnerships.
• Strengthening supply-chain resilience: digitization, multi-sourcing of key APIs, and expanded cold-chain logistics for biologics.
• Quality modernization: batch traceability systems, lean manufacturing programs, and enhanced QA staffing and training.
• Community health programs: targeted vaccination and chronic disease management projects in underserved provinces.
• International expansion: regulatory filings and market entries prioritized across Southeast Asia, Africa, and select European markets.